Literature DB >> 34072509

Modeling-Based Decision Support System for Radical Prostatectomy Versus External Beam Radiotherapy for Prostate Cancer Incorporating an In Silico Clinical Trial and a Cost-Utility Study.

Yvonka van Wijk1, Bram Ramaekers2, Ben G L Vanneste3, Iva Halilaj1, Cary Oberije1, Avishek Chatterjee1, Tom Marcelissen4, Arthur Jochems1, Henry C Woodruff1, Philippe Lambin1.   

Abstract

The aim of this study is to build a decision support system (DSS) to select radical prostatectomy (RP) or external beam radiotherapy (EBRT) for low- to intermediate-risk prostate cancer patients. We used an individual state-transition model based on predictive models for estimating tumor control and toxicity probabilities. We performed analyses on a synthetically generated dataset of 1000 patients with realistic clinical parameters, externally validated by comparison to randomized clinical trials, and set up an in silico clinical trial for elderly patients. We assessed the cost-effectiveness (CE) of the DSS for treatment selection by comparing it to randomized treatment allotment. Using the DSS, 47.8% of synthetic patients were selected for RP and 52.2% for EBRT. During validation, differences with the simulations of late toxicity and biochemical failure never exceeded 2%. The in silico trial showed that for elderly patients, toxicity has more influence on the decision than TCP, and the predicted QoL depends on the initial erectile function. The DSS is estimated to result in cost savings (EUR 323 (95% CI: EUR 213-433)) and more quality-adjusted life years (QALYs; 0.11 years, 95% CI: 0.00-0.22) than randomized treatment selection.

Entities:  

Keywords:  cost-effectiveness; decision support system; external beam radiotherapy; in silico trial; prostate cancer; radical prostatectomy

Year:  2021        PMID: 34072509     DOI: 10.3390/cancers13112687

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  32 in total

1.  The prostate cancer risk stratification (ProCaRS) project: recursive partitioning risk stratification analysis.

Authors:  George Rodrigues; Himu Lukka; Padraig Warde; Michael Brundage; Luis Souhami; Juanita Crook; Fabio Cury; Charles Catton; Gary Mok; Andre-Guy Martin; Eric Vigneault; Jim Morris; Andrew Warner; Sandra Gonzalez Maldonado; Tom Pickles
Journal:  Radiother Oncol       Date:  2013-11-11       Impact factor: 6.280

2.  Development of an isotoxic decision support system integrating genetic markers of toxicity for the implantation of a rectum spacer.

Authors:  Yvonka van Wijk; Ben G L Vanneste; Arthur Jochems; Sean Walsh; Cary J Oberije; Michael Pinkawa; Bram L T Ramaekers; Ana Vega; Philippe Lambin
Journal:  Acta Oncol       Date:  2018-06-28       Impact factor: 4.089

3.  Development of a virtual spacer to support the decision for the placement of an implantable rectum spacer for prostate cancer radiotherapy: Comparison of dose, toxicity and cost-effectiveness.

Authors:  Yvonka van Wijk; Ben G L Vanneste; Sean Walsh; Skadi van der Meer; Bram Ramaekers; Wouter van Elmpt; Michael Pinkawa; Philippe Lambin
Journal:  Radiother Oncol       Date:  2017-08-16       Impact factor: 6.280

Review 4.  Predictive, personalized, preventive, participatory (P4) cancer medicine.

Authors:  Leroy Hood; Stephen H Friend
Journal:  Nat Rev Clin Oncol       Date:  2011-03       Impact factor: 66.675

5.  Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial.

Authors:  J Athene Lane; Jenny L Donovan; Michael Davis; Eleanor Walsh; Daniel Dedman; Liz Down; Emma L Turner; Malcolm D Mason; Chris Metcalfe; Tim J Peters; Richard M Martin; David E Neal; Freddie C Hamdy
Journal:  Lancet Oncol       Date:  2014-08-19       Impact factor: 41.316

6.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

7.  Decomposing cross-country differences in quality adjusted life expectancy: the impact of value sets.

Authors:  Richard Heijink; Pieter van Baal; Mark Oppe; Xander Koolman; Gert Westert
Journal:  Popul Health Metr       Date:  2011-06-23

Review 8.  Decision Support Systems in Oncology.

Authors:  Seán Walsh; Evelyn E C de Jong; Janna E van Timmeren; Abdalla Ibrahim; Inge Compter; Jurgen Peerlings; Sebastian Sanduleanu; Turkey Refaee; Simon Keek; Ruben T H M Larue; Yvonka van Wijk; Aniek J G Even; Arthur Jochems; Mohamed S Barakat; Ralph T H Leijenaar; Philippe Lambin
Journal:  JCO Clin Cancer Inform       Date:  2019-02

Review 9.  Discounting in Economic Evaluations.

Authors:  Arthur E Attema; Werner B F Brouwer; Karl Claxton
Journal:  Pharmacoeconomics       Date:  2018-07       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.